>>> After Hours Summary: ESTC +15.1%, ULTA +11.3%, PATH +11%, PD +7.4% higher on

After Hours Summary: ESTC +15.1%, ULTA +11.3%, PATH +11%, PD +7.4% higher on earnings; DELL -3%, MRVL -2.6% lower on earnings

After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: ESTC +15.1%, IOT +13.6%, ULTA +11.3% (also CFO to retire, names new CFO), PATH +11%, DOMO +7.5%, PD +7.4%, AMWD +4.7%, AMBA +3.2%, ZUMZ +1.2%
Companies trading higher in after hours in reaction to news: ALT +29.1% (announces topline results from MOMENTUM Phase 2 Obesity Trial of Pemvidutide), ELF +2.4% (in sympathy with strong ULTA earnings), LSCC +2% (expands stock repurchase program with new $250 mln authorization), NVRO +1.6% (acquires Vyrsa Technologies), BANC +0.9% (completes merger with PACW), BYON +0.8% (approves a declassification of the Board), DIS +0.6% (reinstates dividend; had been suspended since spring 2020), CCNE +0.6% (names new chairperson), RJF +0.4% (authorizes new $1.5 bln share repurchase program; also increases dividend), EL +0.2% (in sympathy with strong ULTA earnings), MRK +0.1% (Merck says FDA accepted for priority review a new sBLA for KEYTRUDA)

After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: CLSK -15.7%, DELL -3%, MRVL -2.6%
Companies trading lower in after hours in reaction to news: CWAN -4.5% (launches 17 mln share offering), MKL -4% (COO to step down), SMCI -3.8% (stock offering), TSLA -1.4% (releases prices of its new Cybertruck; starts at $60,990), TMC -0.9% (files $100 mln mixed shelf securities offering), CRM -0.7% (files mixed shelf securities offering), SGEN -0.2% (FDA grants priority review for sBLA of PADCEV with KEYTRUDA), GD -0.2% (will compete with Tactical Systems for a $655 mln US Army contract)

Business Of Fashion : How Ozempic Changed the Face of Beauty

How Ozempic Changed the Face of Beauty
Famed for speedy weight loss, the effects of the prescription-only drug are now shifting beauty standards.

KEY INSIGHTS
  • Ozempic’s off-label use for weight loss is creating a new beauty concern, dubbed “Ozempic face.”
  • Experts predict that its prevalence will lead to wider uptake of bio-stimulating products, such as Sculptra and Radiesse, and changes in how plastic surgery is carried out. Meanwhile, treatments and products for facial sculpting like contouring sticks are seeing a downshift.
  • Aesthetic clinics and chains, a new favourite target for private equity and venture capital, are poised to cash in on the moment.

When 29-year-old Maria, a social media executive from New York, arrived for a routine Botox appointment, she was surprised by an elective add-on her doctor proffered: Ozempic.

“[My doctor] said, ‘Oh, do you want a shot of Ozempic while you’re here?’ like she was offering me an extra napkin or something.” On hearing she could lose up to fifteen pounds that week, Maria took it, later finding the subsequent nausea overwhelming. But on the Upper East Side, where she had her shot, and across the nation, more and more people are collecting a weekly prescription — covertly or not.

In the blink of an eye, Ozempic, otherwise known as semaglutide, and its competitors like Wegovy and Rybelsus went from a little-known medicine for diabetics to a cultural touchstone. Its off-label use for weight loss, and fast, is what catapulted the drug from pharmaceutical-rep chatter to the preserve of Hollywood starlets, socialites and elite zip codes.

The drug’s prevalence has led to less consumption of candy and beer, per Walmart, and the rise of Ozempic face, a “suddenly gaunt, hollow-looking … prematurely aged face,” leading clients to change their minds on once-undesirable roundness and plumpness, said Dr. Ahmed El Muntasar, a general and aesthetic practitioner in the UK.

Moreover, Ozempic’s rise has yielded a hit on the “snatched” look. Spate, a consumer trends platform, found that social media searches for “contouring” are down 10.6 percent year-on-year, with co-founder Yarden Horwitz adding that while contouring techniques are slowing down in search, bronzing products, which create more of a healthy all-over glow, are up 33 percent since last year.

Skin-tightening lasers like Morpheus8, which can cost around $1,700 for a single face-and-neck session, and microdroplet treatments like Profhilo and the newly-FDA approved Skinvive that improve skin hydration the fine lines caused by sagging skin are also trending, experts said. Microdroplet treatments can cost upwards of $500 in prestige clinics.

“In my practice, I see a lot of people who didn’t need any facial filler because they were heavier people,” said Dr. Corey L. Hartman, a board-certified dermatologist with an aesthetic practice in Birmingham, Alabama. Now, those same patients are starting to request volumising treatments to replenish what Ozempic has taken away.

Plump It Up
The idea of roundness as desirable is an about-face from the contouring era that’s persisted since the mid 2010s, where sculpting ruled supreme. Popularised by social media influencers and celebrities, contouring accentuates shadow and definition, giving the face a sculpted look. In its heyday, cosmetics brands like Anastasia Beverly Hills and Fenty Beauty rushed to add sculpting sticks, palettes and kits to their line-up. In 2022, the craze went even further, with a procedure known as buccal fat removal, which can cost around $9,500, becoming popularised. A permanent, surgical procedure, it slims down the fat pads in the cheeks for more angular appearance.

But now some of those same patients are looking to be re-plumped. The likes of Dr. Hartman and Dr. El Muntasar can offer a range of procedures, including injectable dermal fillers composed of hyaluronic acid to give instant volume or bio-stimulating injections such as Sculptra, which can cost upwards of $1,000 per syringe, that help the skin produce more collagen to replenish what’s lost.

Dr. Hartman noted interest in Sculptra in his clinic is up threefold this year alone. Lisa Goodman, founder and chief of the bicoastal Goodskin Clinics pointed to the rising popularity of a treatment called Renuva — around $1,800 per syringe in some clinics — that stimulates the production of fat. Goodman said that clients view it as more holistic, or less fake, “because it stimulates your own fat cells, rather than just filling with pure volume.”

For Dr. Robert Schwarcz, an oculofacial plastic surgeon based in New York’s well-heeled Upper East Side, Ozempic has meant a change to an old faithful: the facelift. For a facelift to look natural, there still needs to be a good amount of volume under the skin to play around with. “Oftentimes, [patients] now just don’t have enough fat on their face,” he said. Instead, he has to harvest the fullness from other parts of the body via a fat graft.

The volumisation side of Dr. Schwarcz’s practice has expanded 25 percent, including client requests for fillers and fat grafting.

The Investment Opportunity
Aesthetics clinics and medical spas are in a strong position to capture residuals from the Ozempic boom. Research from consulting group McKinsey & Co. indicates that the US beauty services sector is expected to grow by 7 percent per year up to 2027, nearing $80 billion as a sector.

With a flood of new Ozempic patients looking for the next facial filler, clinics are expected to become more attractive investment targets. Just last year private equity juggernaut KKR took a minority stake in SkinSpirit, a US chain specialising in injectables.

Investors favour aesthetics practices due to their relatively straightforward financial modelling. Once a business has a certain number of units open, it’s easy to predict how many more can be opened in five years, providing the clinic concept is proven. What’s more, consumers show no signs of cutting back — partly because they can’t self-administer fillers like they might DIY a manicure, but also because it’s become normalised. A 2022 audit by the British Association of Aesthetic Plastic Surgeons (BAAPs) showed a 124 percent increase in Botox treatments against the previous year.

Dr. Hartman added that for the best results, bio-stimulating treatments require a few sessions, spaced apart. That’s more chargeable chair time for the proprietor.

There’s also the fact that one change often begets another. “[Patients] often come in towards the middle of their weight loss. And they say, ‘How do I make my face match my body?” said Goodman.

Business Of Fashion : Audemars Piguet Launches Collab with Travis Scott in Lates

Audemars Piguet Launches Collab with Travis Scott in Latest Culture Play
A limited-edition Royal Oak watch and co-branded merch line are set to be revealed Friday.

Swiss luxury watch brand Audemars Piguet is set to renew its longstanding ties to American pop culture with the release of a watch collaboration with hip-hop star Travis Scott and his label Cactus Jack Records.

In partnership with Scott, Audemars Piguet will release a limited-edition version of its Royal Oak watch Thursday in a new ceramic, as well as putting out a capsule collection of co-branded merchandise from the Swiss watchmaking house and Cactus Jack.

The new watch will be formally unveiled this evening and will feature a number of motifs from Scott’s Cactus Jack label, including a moon phase decorated with a luminous version of the hip brand’s logo — a smiley face with its mouth sewn shut.

“Travis could raise an army,” said Audemars Piguet’s chief executive François-Henri Bennahmias in an exclusive interview with The Business of Fashion. “He’s got such a power. People follow him in a major way.”

Scott, 32, is one of the most successful hip-hop artists of his generation. His fourth studio album Utopia, released in July, had more than 650 million global streams in its opening week, making it the most commercially successful hip-hop album of the year.

The collaboration is likely to be remembered not just for a wristwatch co-designed by Scott, but for the collection of hoodies, T-shirts, jackets, pyjamas, shorts and caps sold through Scott’s own e-commerce platform.

“People will go nuts when they know that AP and Travis have made merch together,” said Bennahmias. “It breaks pretty much every code. Is it going to be successful? We could have multiplied the quantity by at least 10 times and still been successful.”

Audemars Piguet, Bennahmias said, would make “zero” profit from the clothes and accessories, which instead will fund charities including the Cactus Jack Foundation, which grants scholarships to disadvantaged young people.

The collaboration will also be remembered as François-Henri Bennahmias’s swan-song before he retires from the role of Audemars Piguet’s chief executive at the end of this year, a post he took up in 2012 having joined the company almost 30 years ago.

Bennahmias is recognised as one of the watch industry’s most disruptive and influential figures, transforming the family-owned company from a dusty high-end watchmaker into one of the most recognised and in-demand names in luxury.

It was Bennahmias who, while running the company’s US operations, brought it together with Muhammad Ali and Arnold Schwarzenegger for the Time To Give auction in the year 2000, and then forged an unlikely alliance to street culture with the Royal Oak Offshore Jay-Z 10th Anniversary in 2005, a watch collab widely considered by industry observers to be a tipping point for the typically conservative Swiss watch industry.

AP has since continued to align itself with popular culture, nurturing high-profile relationships with stars of film, music, sports and the arts, including LeBron James, Kevin Hart and Ed Sheeran, powering rapid sales growth for its watches which have an average price of 42,000 Swiss francs ($47,970).

Bennahmias said he expects Audemars Piguet’s 2023 revenues to grow by around 200,000 Swiss francs to top 2.3 billion Swiss francs ($2.6 billion).

The partnership with Scott might have been announced sooner. In June this year, a Texas grand jury declined criminal charges brought against Scott after 10 people, including a nine-year-old girl, were killed in a crush at a festival he founded in 2021. Scott was widely criticised for his response to the Astroworld Festival disaster. Bennahmias declined to comment on the incident, but said that Audemars Piguet had waited until the jury’s decision before activating the collaboration, having first met Scott in 2020 when he was a client.

>>> Johnson & Johnson lowers its FY23 earnings outlook due to the previously ann

Johnson & Johnson lowers its FY23 earnings outlook due to the previously announced acquisition of Laminar; will reduce FY24 earnings by $0.15 (154.66 +2.54)
  • Co noted that as a result of its previously announced acquisition of Laminar, it will adjust its expected adjusted EPS for FY23, reducing it by $0.17.
  • Co issues lowered guidance for FY23 (Dec), sees EPS of $9.90-9.96 (down from $10.07-10.13), excluding non-recurring items, vs. $10.09 FactSet Consensus.
  • Additionally, the asset acquisition is expected to have an approximate negative $0.15 EPS impact in fiscal year 2024.

>>> Marvell beats by $0.01, beats on revs; guides Q4 EPS in-line, revs in-line (

Marvell beats by $0.01, beats on revs; guides Q4 EPS in-line, revs in-line (55.73 -0.37)
  • Reports Q3 (Oct) earnings of $0.41 per share, excluding non-recurring items, $0.01 better than the FactSet Consensus of $0.40; revenues fell 7.7% year/year to $1.42 bln vs the $1.40 bln FactSet Consensus.
    • Data Center segment sales fell 11% yr/yr but rose 21% sequentially to $555.8 mln, this is above guidance of growth in the mid-teens sequentially.
    • Enterprise Networking segment sales fell 28% yr/yr and fell 17% sequentially to $271.1 mln. The company had expected a low-teens sequential decline in Q3.
    • Carrier Infrastructuresegment sales grew 17% yr/yr and grew 15% sequentially to $316.5 mln. Co had guided to CI segment revs growing low single-digits sequentially, driven by wireless.
    • Consumer segment revenue fell 5% yr/yr but rose 1% sequentially to $168.7 mln.
    • Automotive/Industrial segment revenue rose 26% yr/yr but fell 3% sequentially to $106.5 mln.
  • Co issues in-line guidance for Q4 (Jan), sees EPS of $0.41-0.51, excluding non-recurring items, vs. $0.49 FactSet Consensus; sees Q4 revs of $1.349-1.491 bln vs. $1.46 bln FactSet Consensus.
  • "Revenue from our datacenter end market grew over 20% sequentially in the third quarter, and we expect growth of over 30% sequentially in our fourth quarter," said Matt Murphy, Marvell's Chairman and CEO. "The diversification of our portfolio is serving us well, with strong growth from AI and cloud carrying us through a softening demand environment in other end markets. These dynamics are reflected in our forecast for overall revenue to be flat sequentially in the fourth quarter at the midpoint of guidance."

>>> Ambarella beats by $0.11, beats on revs; guides JanQ revs in-line; expects r

Ambarella beats by $0.11, beats on revs; guides JanQ revs in-line; expects revenue growth in FY25 (58.71 +1.37)
  • Reports Q3 (Oct) loss of ($0.28) per share, excluding non-recurring items, $0.11 better than the FactSet Consensus of ($0.39); revenues fell 39.1% year/year to $50.6 mln vs the $50.01 mln FactSet Consensus.
  • Co issues in-line guidance for Q4 (Jan), sees Q4 revs of $50-53 mln vs. $50.35 mln FactSet Consensus.
  • Co added, "Our customers appear to be making progress with their inventory reduction efforts and we expect to return to revenue growth in Fiscal 2025."

>>> Dell beats by $0.42, misses on revs (75.94 +0.90)

Dell beats by $0.42, misses on revs (75.94 +0.90)
  • Reports Q3 (Oct) earnings of $1.88 per share, excluding non-recurring items, $0.42 better than the FactSet Consensus of $1.46; revenues fell 10.0% year/year to $22.25 bln vs the $23.01 bln FactSet Consensus.
    • Infrastructure Solutions Group delivered third quarter revenue of $8.5 billion, flat sequentially and down 12% year-over-year. Servers and networking revenue was $4.7 billion, with 9% sequential growth driven by AI-optimized servers. Storage revenue was $3.8 billion, down 8% sequentially with demand strength in unstructured data solutions and data protection. Operating income was $1.1 billion.
    • Client Solutions Group delivered third quarter revenue of $12.3 billion, down 11% year-over-year and 5% sequentially. Commercial client revenue was $9.8 billion, and Consumer revenue was $2.4 billion. Operating income was $925 million.
    • "Our servers and networking business was up 9% sequentially fueled by customer interest in generative AI. And heading into FY25, we expect revenue growth given the tailwinds to our business." Dell continued to expand its broad portfolio to help customers meet their performance, cost and security requirements across clouds, on premises and at the edge.

>>> Walt Disney announces a cash dividend of $0.30/share in respect of the secon

Walt Disney announces a cash dividend of $0.30/share in respect of the second half of fiscal year 2023; company had suspended its dividend in the spring of 2020 (93.69 +0.19)
  • "This has been a year of important progress for The Walt Disney Company, defined by a strategic restructuring and a renewed focus on long-term growth," said Mark Parker, Chairman of the Board. "As Disney moves forward with its key strategic objectives, we are pleased to declare a dividend for our shareholders while we continue to invest in the company's future and prioritize meaningful value creation."

>>> US Close Dow +1.47% S&P +0.38% Nasdaq -0.23% Russell +0.29%

Closing Stock Market Summary
Today's price action was somewhat mixed. The Dow Jones Industrial Average was a relative outperformer, climbing 1.5%, due in part to a big gain in Salesforce (CRM 251.90, +21.55, +9.4%) after impressing with its earnings results and outlook after yesterday's close.

The S&P 500 and Nasdaq Composite, meanwhile, spent most of the session pinned in negative territory due to lagging mega cap constituents. The Vanguard Mega Cap Growth ETF (MGK) closed with a 0.1% loss and the Nasdaq Composite fell 0.2%.

An uptick in buying activity in the last half hour of trading left the S&P 500 near its high of the day with a 0.4% gain. The equal-weighted S&P 500, which outperformed the market-cap weighed index throughout the session, rose 0.9% today.

The S&P 500 sectors also reflected the underperformance of mega cap stocks. Communication services (-1.0%), consumer discretionary (-0.2%), and information technology (-0.1%) were the only sectors to register a decline today. The health care (+1.3%), industrials (+1.1%), financials (+1.0%), and materials (+1.0%) sectors all climbed at least 1.0%.

The outperformance of the broader market comes in the wake some economic data today that featured a moderation in income and spending, and disinflation in the PCE Price Indexes in October, a much stronger-than-expected Chicago PMI for November, and a relatively low level of initial jobless claims.

Treasury yields backed up some in response to the data, which kept some buyer enthusiasm in check in the stock market. The 2-yr note yield, at 4.61% before 8:30 a.m. ET, settled four basis points higher at 4.70%. The 10-yr note yield, at 4.27% before the data, settled eight basis points higher at 4.35%. Still, yields have come down a lot since the start of November. The 2-yr note and 10-yr note declined 38 basis points and 53 basis points, respectively, this month.

In other news, WTI crude oil futures fell 2.4% today to $75.96/bbl after briefly climbing past their 200-day moving average (78.15). On a related note, several OPEC+ countries confirmed additional voluntary cuts to the total of 2.2 million barrels per day, beginning January 1 through the end of March 2024.
  • Nasdaq Composite: +35.9%
  • S&P 500: +19.0%
  • Dow Jones industrial Average: +8.5%
  • S&P Midcap 400: +5.5%
  • Russell 2000: +2.7%

Reviewing today's economic data:
  • October Personal Income 0.2% (consensus 0.2%); Prior was revised to 0.4% from 0.3%; October Personal Spending 0.2% (consensus 0.2%); Prior 0.7%; October PCE Prices 0.0% (consensus 0.1%); Prior 0.4%; October PCE Price - Core 0.2% (consensus 0.2%); Prior 0.3%
    • The key takeaway from this report is the disinflation seen in the PCE Price Indexes, which is good; however, the 3.5% increase in core PCE, which is what the Fed focuses on, remains well above the 2.0% target. It's moving in the right direction fortunately, but that isn't the type of reading that will move the Fed to think about cutting rates soon.
  • Weekly Initial Claims 218K (consensus 215K); Prior was revised to 211K from 209K; Weekly Continuing Claims 1.927 mln; Prior was revised to 1.841 mln from 1.840 mln
    • The key takeaway from the report is that layoff activity remains relatively subdued, which is a good thing. The bad thing, and what fits with a softening labor market, is that it is becoming more difficult to find a job after a layoff.
  • November Chicago PMI 55.8 (consensus 45.0); Prior 44.0
  • October Pending Home Sales -1.5% (consensus -2.3%); Prior was revised to 1.0% from 1.1%

Friday's economic calendar features:
  • 9:45 ET: Final November S&P Global U.S. Manufacturing PMI (prior 49.4)
  • 10:00 ET: November ISM Manufacturing Index (consensus 47.5%; prior 46.7%) and October Construction Spending (consensus 0.3%; prior 0.4%)